NURS 751 Week 6 Evidence-Based Article Review of a Randomized Trial in ARFID Example

Weight Gained, Severity Unchanged: An Evidence-Based Review of a 2026 Randomized Trial Comparing Family-Based and Individual Treatment for Underweight Children With ARFID

Introduction

Avoidant/restrictive food intake disorder, or ARFID, was introduced in the DSM-5 to describe people whose restriction of food leads to weight loss, nutritional deficiency, dependence on supplements or impaired functioning, and is driven by low interest in eating, sensory sensitivity or fear of aversive consequences such as choking, rather than by concern about body shape (American Psychiatric Association, 2013). Children with ARFID are often seen first by pediatric and psychiatric clinicians, and families frequently ask which treatment to pursue. Until recently, the evidence came mostly from case reports and case series. This review examines one of the first randomized trials of psychological treatment for ARFID, a 2026 trial by Lock et al. comparing family-based treatment with an individual therapy for underweight children.

Summary of the Article

Purpose and Design

Lock et al. (2026) set out to test whether family-based treatment adapted for ARFID was more effective than individual psychoeducational motivation therapy for underweight children aged 6 to 12. The study was a randomized clinical trial registered with ClinicalTrials.gov (NCT04450771). The primary outcome was the difference between groups in change in percent of estimated body weight from baseline to the end of treatment.

Sample and Interventions

Ninety-eight children with ARFID were randomized. Both treatments consisted of 14 sessions delivered by telehealth over four months. Family-based treatment placed parents in charge of increasing their child's intake and dietary range, while psychoeducational motivation therapy worked individually with the child on understanding nutrition and motivation to eat.

Measures and Results

Weight and height, eating-related thoughts and ARFID behaviors were assessed online at baseline, one month, two months and the end of treatment by assessors who did not know which treatment each child received. At the end of treatment, family-based treatment was superior to individual therapy in increasing percent of estimated body weight. There were no differences between groups in improvement in overall ARFID severity or other ARFID symptoms. In exploratory analyses, baseline severity moderated the effect: the children with the most severe symptoms improved significantly more with family-based treatment (Lock et al., 2026).

Critique

Strengths

The trial has several features that raise confidence in its main result. Randomization protects against the most common source of bias in treatment comparisons, that families who choose one treatment differ from those who choose another. Outcome assessors were masked to treatment, which matters because judgments of eating behavior can be influenced by knowing who received which treatment. The trial was registered in advance and named a single primary outcome, which limits the temptation to report whichever result looked best. Using the same number of sessions in both arms means the weight difference cannot be explained by more contact time. Delivering both treatments by telehealth also tests a format many families now prefer.

Limitations

The limits are equally important. First, the primary outcome was weight, a reasonable target for underweight children but not the whole of ARFID, which is defined as much by limited variety and fear as by weight. On overall ARFID severity, the two treatments did not differ. Second, the finding that the most severely affected children did better with family-based treatment comes from exploratory analyses, which generate hypotheses rather than confirm them. Third, the sample was limited to underweight children aged 6 to 12, so the results do not apply to adolescents, adults or children of normal weight whose ARFID shows up as limited variety or supplement dependence. Fourth, with 98 participants divided between two arms, the trial may have been too small to detect modest differences in secondary outcomes. A trial can answer its own question cleanly and still leave the family's question, will my child eat more kinds of food, partly open.

Level of Evidence

Being a single randomized trial, it sits at level II of the Melnyk and Fineout-Overholt evidence hierarchy. It is strengthened when read alongside the broader literature. A 2026 meta-analysis of psychological therapies for adolescents and adults with ARFID found medium reductions in ARFID psychopathology (g = 0.63) and large increases in weight (g = 1.26) from before to after treatment, but noted that the evidence base relied mainly on case studies and case series, with very few randomized designs (Winten et al., 2026). The Lock et al. (2026) trial therefore adds the kind of controlled evidence the field has lacked, though for children rather than the older populations in the meta-analysis.

Application to Practice

For the psychiatric nurse practitioner, the trial supports a clear recommendation for one group: underweight children with ARFID, particularly those with severe symptoms, should be referred to family-based treatment where it is available, including by telehealth. For children who are not underweight, individual therapy focused on education and motivation appears to improve symptoms comparably, which gives families a reasonable alternative. Consider a composite 9-year-old who eats only six foods, has fallen from the 40th to the 8th percentile for weight and gags at new textures. The trial suggests that her parents, coached to take charge of meals, are her best route to regaining weight, and that her sensory fears will still need attention as treatment continues. The nurse practitioner's role includes monitoring growth and nutritional labs, screening for co-occurring anxiety and autism, and explaining to parents that weight restoration is the first goal but not the last.

Conclusion

Lock et al. (2026) provide randomized evidence that family-based treatment produces more weight gain than individual therapy for underweight children with ARFID, with similar improvement in overall symptom severity and a suggestion that the most severely affected children benefit most from family treatment. The trial's randomization, masked assessment and registration make its primary finding credible, while its narrow age and weight range, its weight-centered outcome and the exploratory status of the severity finding limit how far it can be extended. It is an important step for a field built largely on case reports.

References

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596

Lock, J., Matheson, B., Jo, B., Bohon, C., Datta, N., Whyte, A., Boyce, H., Gurcan, H. Y., Cogburn, A. E., & Kim, B. (2026). Family vs individual treatment for children with avoidant/restrictive food intake disorder: A randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry. Advance online publication. https://doi.org/10.1016/j.jaac.2026.04.007

Winten, C. G., Strodl, E., Kambanis, P. E., Ross, L. J., & Thomas, J. J. (2026). A systematic review and meta-analysis of psychological therapies for avoidant/restrictive food intake disorder (ARFID) in adolescents and adults. International Journal of Eating Disorders, 59(7), 1403-1425. https://doi.org/10.1002/eat.70086